Effects of Ferroprotin 1 expression on tumorigenesis, invasiveness and survival of patients with breast cancer

Objective To explore the effect of Ferroprotin 1 expression on tumorigenesis, invasiveness and survival of breast cancer. Methods In this study, 100 breast cancer patients were enrolled. IHC SP was used to detect the expression of Ferroprotinl in paraffin-embedded tissues. The association of Ferroprotin 1 expression and clinieo-pathologieal parameters was evaluated by ehi-square test. Survival analysis was calculated by Kaplan-Meier model and Log-rank test. Results The expression of Ferroprotin 1 was significantly higher in para-cancerous normal tissues （37/100, 37% ） than that in breast cancer tissues （24/100, 24% ; P =0. 046）. In these with positive axillary LN, there were more with low expression level of Ferroprotin 1 （ 36/40,90% ） than those with high expression level （ 4/40, 10% ）, P = 0. 007. More patients with low Ferroprotinl were at advanced stage than those with high ferroprotinl [ Ⅲ 44/57（77.2% ） ; IV 17/18 （ 94. 4% ） ] （ P = 0. 05 ）. No significant association was found between ferroprotinl and tumor grade, histology type, ER/PR, HER2, tumor size （P 〉0. 05）. Ferroprotinl has no significant effect on breast cancer survival （ P = 0. 591 ） by Kaplan-Meier curve and Log-rank test. Conclusions Low Ferroprotin 1 may lead to the tumorigenesis of breast cancer. Downregulated Ferroprotinl promotes the LN involvement of breast cancer and accompanies with more advanced disease. However Ferroprotinl might not play an important role in the survival of breast cancer. Key words: Breast neoplasms;  Immunohistochemistry;  Prognosis;  Ferroprotinl